The fine print of the over Rs 13,000 crore Mankind-BSV deal deciphered

Delhi-based pharma major Mankind Pharma will emerge as the leader in the women’s health portfolio in the India Pharma Market (IPM) after it agreed to a Rs 13,630-crore deal to acquire 100 per cent stake in Bharat Serums and Vaccines (BSV), senior Mankind officials said. Not only this, the deal will also open doors to overseas market for Mankind Pharma, which currently earns 92 per cent of its revenue from the Indian market.

After the deal, the combined entity will generate approximately 13 percent of revenues from the international market, with the remainder from